{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:00:26Z","timestamp":1790787626307,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Intravitreal aflibercept 8\u00a0mg was developed to extend treatment intervals and reduce injection burden in neovascular age-related macular degeneration (nAMD). We evaluated visual, anatomical, and durability outcomes over 18 months in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study included 102 eyes of 95 treatment-na\u00efve nAMD patients commencing aflibercept 8\u00a0mg at a UK tertiary centre. All eyes received three loading injections followed by a treat-and-extend protocol. Best-recorded visual acuity (BRVA), central subfield thickness (CST), intraretinal fluid (IRF), subretinal fluid (SRF), and macular haemorrhage were assessed at baseline, post-loading, 12 months, and 18 months. Linear and generalised mixed-effects models were applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean patient age was 81.1\u2009\u00b1\u20096.5 years; 68.4% were female. Mean BRVA was 62.5\u2009\u00b1\u200912.4 letters at baseline, 67.5\u2009\u00b1\u200913.7 post-loading, 66.8\u2009\u00b1\u200915.3 at 12 months (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009102), and 65.5\u2009\u00b1\u200918.5 letters at 18 months (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200973). Mean CST was 317.1\u2009\u00b1\u200995.4\u00a0\u03bcm at baseline, 237.9\u2009\u00b1\u200945.2\u00a0\u03bcm post-loading, 236.3\u2009\u00b1\u200951.7\u00a0\u03bcm at 12 months, and 220.6\u2009\u00b1\u200932.2\u00a0\u03bcm at 18 months (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200973). At 12 months, 51.9% of eyes achieved treatment intervals of \u2265\u200912 weeks, increasing to 73.9% at 18 months. No cases of endophthalmitis were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Aflibercept 8\u00a0mg achieved sustained visual acuity, significant anatomical improvement, and progressively extended treatment intervals over 18 months in treatment-na\u00efve nAMD within routine clinical practice, supporting its effectiveness in reducing treatment burden without compromising disease control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07513-9","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:00:41Z","timestamp":1790740841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eighteen-month real-world outcomes of intravitreal aflibercept 8\u00a0mg in treatment-na\u00efve neovascular age-related macular degeneration: a UK single-centre experience"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2582-4341","authenticated-orcid":false,"given":"Benjamin","family":"Scrivens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areti","family":"Papazacharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-3901","authenticated-orcid":false,"given":"Panayiotis","family":"Maghsoudlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4990-9413","authenticated-orcid":false,"given":"Serena","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"7513_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"7513_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U (2024) Age-related macular degeneration: a review. JAMA 331:147\u2013157. https:\/\/doi.org\/10.1001\/jama.2023.26074","journal-title":"JAMA"},{"key":"7513_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMcp2102061","volume":"385","author":"RS Apte","year":"2021","unstructured":"Apte RS (2021) Age-related macular degeneration. N Engl J Med 385:539\u2013547. https:\/\/doi.org\/10.1056\/NEJMcp2102061","journal-title":"N Engl J Med"},{"key":"7513_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Mon\u00e9s J, Richard G, Bandello F (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98:1144\u20131167. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305702","journal-title":"Br J Ophthalmol"},{"key":"7513_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD et al (2012) Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"7513_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","volume":"23","author":"J Boyle","year":"2018","unstructured":"Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G (2018) Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med 23:127\u2013140. https:\/\/doi.org\/10.1080\/13548506.2016.1274040","journal-title":"Psychol Health Med"},{"key":"7513_CR7","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","volume":"38","author":"C Goodchild","year":"2024","unstructured":"Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S (2024) Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye 38:3059\u20133064. https:\/\/doi.org\/10.1038\/s41433-024-03218-7","journal-title":"Eye"},{"key":"7513_CR8","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.xops.2025.100744","volume":"5","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Guymer R, Artignan A, Downey A, Singh RP (2025) Real-world evidence for faricimab in neovascular age-related macular degeneration and diabetic macular edema: a scoping review. Ophthalmol Sci 5:100744. https:\/\/doi.org\/10.1016\/j.xops.2025.100744","journal-title":"Ophthalmol Sci"},{"key":"7513_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s J, Singh RP, Bandello F, Souied E, Liu X, Gale R (2020) Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world. Ophthalmologica 243:1\u20138. https:\/\/doi.org\/10.1159\/000502747","journal-title":"Ophthalmologica"},{"key":"7513_CR10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A et al (2023) Effect of high-dose intravitreal aflibercept, 8\u00a0mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol 141:834\u2013842. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2421","journal-title":"JAMA Ophthalmol"},{"key":"7513_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ophtha.2025.08.022","volume":"133","author":"JF Korobelnik","year":"2026","unstructured":"Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D et al (2026) Intravitreal aflibercept 8\u00a0mg in neovascular age-related macular degeneration: ninety-six-week results from the randomized phase 3 PULSAR trial. Ophthalmology 133:39\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2025.08.022","journal-title":"Ophthalmology"},{"key":"7513_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40942-025-00665-6","volume":"11","author":"J Cattaneo","year":"2025","unstructured":"Cattaneo J, De Oliveira Figueiredo EC, Montesel A, Vermeirsch S, Eandi CM (2025) Early real-world outcomes of intravitreal aflibercept 8\u00a0mg in treatment-na\u00efve neovascular AMD: AI-assisted fluid volume analysis. Int J Retina Vitr 11:42. https:\/\/doi.org\/10.1186\/s40942-025-00665-6","journal-title":"Int J Retina Vitr"},{"key":"7513_CR13","doi-asserted-by":"publisher","first-page":"e002091","DOI":"10.1136\/bmjophth-2024-002091","volume":"10","author":"D Sambhara","year":"2025","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA (2025) Real-world efficacy and safety of 8\u00a0mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol 10:e002091. https:\/\/doi.org\/10.1136\/bmjophth-2024-002091","journal-title":"BMJ Open Ophthalmol"},{"key":"7513_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40123-025-01305-w","volume":"15","author":"G Grimaldi","year":"2026","unstructured":"Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A et al (2026) One-year real-world outcomes of aflibercept 8\u00a0mg in treatment-na\u00efve neovascular age-related macular degeneration: a Swiss Retina Research Network report. Ophthalmol Ther 15:1069\u20131082. https:\/\/doi.org\/10.1007\/s40123-025-01305-w","journal-title":"Ophthalmol Ther"},{"key":"7513_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127:616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004","journal-title":"Ophthalmology"},{"key":"7513_CR16","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41433-022-02231-y","volume":"37","author":"T Mathis","year":"2023","unstructured":"Mathis T, Holz FG, Sivaprasad S et al (2023) Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye 37:1758\u20131765. https:\/\/doi.org\/10.1038\/s41433-022-02231-y","journal-title":"Eye"},{"key":"7513_CR17","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41433-025-03765-7","volume":"39","author":"V Sarao","year":"2025","unstructured":"Sarao V, Veritti D, Bonini F, Martin AA, Lanzetta P (2025) Early intraocular pressure dynamics following aflibercept 8\u00a0mg versus aflibercept 2\u00a0mg: a propensity score-matched analysis. Eye 39:1933\u20131939. https:\/\/doi.org\/10.1038\/s41433-025-03765-7","journal-title":"Eye"},{"key":"7513_CR18","doi-asserted-by":"publisher","first-page":"e88617","DOI":"10.7759\/cureus.88617","volume":"17","author":"P Gartaganis","year":"2025","unstructured":"Gartaganis P, Khamis N, Hamoud Bedan A et al (2025) A comparative assessment of intraocular pressure changes after aflibercept 8\u00a0mg and faricimab-svoa intravitreal injections in wet age-related macular degeneration. Cureus 17:e88617. https:\/\/doi.org\/10.7759\/cureus.88617","journal-title":"Cureus"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07513-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07513-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07513-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:05:35Z","timestamp":1790784335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07513-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":18,"alternative-id":["7513"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07513-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was reviewed and approved by the Clinical Governance and Audit Team of Bristol NHS Foundation Trust (reference MEDRET\/CA\/2024-25\/05), which confirmed that formal research ethics committee review was not required as the work constituted analysis of routinely collected clinical data. All procedures were performed in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","label":"Ethics approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Individual informed consent was waived by the approving body owing to the retrospective design and the use of fully de-identified clinical data collected during routine care.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No individually identifiable data or images are reported.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clare Bailey: advisory board for Bayer, Roche, Alimera Sciences, Janssen, Apellis, Boehringer-Ingelheim; lecture fees\/travel support from Bayer, Roche, Alimera Sciences, Apellis. Serena Salvatore: advisory board for Advanz Pharma, Bayer, Roche, Alimera Sciences; speaker fees\/travel support from Abbvie, Sandoz, Alimera Sciences, Bayer, Roche. Benjamin Scrivens: educational grant from Roche. Pierluigi Daniele, Areti Papazacharia, Ahmed Donia, and Panayiotis Maghsoudlou declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}